IMPACT trial results should not change current standard of care of 100 days for cytomegalovirus prophylaxis

American Journal of Transplantation

Volumn 11, Issue 1, 2011, Pages 18-21

  Kalil, A C ^a   Sun, J ^b   Florescu, D F ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Cytomegalovirus; prophylaxis; valganciclovir

Indexed keywords

ACICLOVIR; GANCICLOVIR; VALACICLOVIR; VALGANCICLOVIR;

CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; EVALUATION; HUMAN; PRIORITY JOURNAL; REVIEW; STANDARD; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; GANCICLOVIR; KIDNEY TRANSPLANTATION; RANDOM ALLOCATION; RESEARCH DESIGN; STANDARD OF CARE;

EID: 78650886599     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2010.03342.x     Document Type: Review

References (16)

1. Humar A, Lebranchu Y, Vincenti F, et al,. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 2010; 10: 1228-1237.
2. Altman DG, Schulz KF, Moher D, et al,. The revised CONSORT statement for reporting randomized trials: Explanation and elaboration. Ann Int Med 2001; 134: 663-694. (Pubitemid 32322245)
3. Chalmers TC, Celano P, Sacks HS, Smith H Jr,. Bias in treatment assignment in controlled clinical trials. N Engl J Med 1983; 309: 1358-1361.
4. Schulz KF, Chalmers I, Hayes RJ, Altman DG,. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995; 273: 408-412.
5. Schulz KF, Grimes DA,. Blinding in randomised trials: Hiding who got what. Lancet 2002; 359: 696-700.
6. Dmitrienko S, Yu A, Balshaw R, Shapiro RJ, Keown PA, Genome Canada Biomarkers in Transplantation Group. The use of consensus guidelines for management of cytomegalovirus infection in renal transplantation. Kidney Int 2007; 72: 1014-1022.
7. Gooley TA, Leisenring W, Crowley J, Storer BE,. Estimation of failure probabilities in the presence of competing risks: New representations of old estimators. Stat Med 1999; 18: 695-706.
8. Alberti C, Metivier F, Landais P, Thervet E, Legendre C, Chevret S,. Improving estimates of event incidence over time in populations exposed to other events: Application to three large databases. J Clin Epidemiol 2003; 56: 536-545.
9. Fine JP, Gray RJ,. A Proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496-509.
10. Paya C, Humar A, Dominguez E, et al,. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4: 611-620.
11. Singh N,. Late-onset cytomegalovirus disease as a significant complication in solid organ transplant recipients receiving antiviral prophylaxis: A call to heed the mounting evidence. Clin Infect Dis 2005; 40: 704-708.
12. Kalil AC, Freifeld AG, Lyden ER, Stoner JA,. Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: An evidence-based reassessment of safety and efficacy. PLoS One 2009; 4: e5512.
13. Kalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG,. Meta-analysis: The efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Int Med 2005; 143: 870-880.
14. Hodson EM, Craig JC, Strippoli GF, Webster AC,. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Coch Database Syst Rev 2008: CD003774.
15. Small LN, Lau J, Snydman DR,. Preventing post-organ transplantation cytomegalovirus disease with ganciclovir: A meta-analysis comparing prophylactic and preemptive therapies. Clin Infect Dis 2006; 43: 869-880.
16. Fiddian P, Sabin CA, Griffiths PD,. Valacyclovir provides optimum acyclovir exposure for prevention of cytomegalovirus and related outcomes after organ transplantation. J Infect Dis 2002; 186 (Suppl 1): S110-S115.